Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 13th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Cigna Group (NYSE:CI) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 11/13/2025.

Eli Lilly and Company Trading Up 1.3%

NYSE:LLY traded up $13.61 on Friday, hitting $1,070.49. 2,474,078 shares of the stock were exchanged, compared to its average volume of 4,024,154. The stock has a fifty day moving average of $956.00 and a 200-day moving average of $828.10. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.01 trillion, a PE ratio of 52.38, a PEG ratio of 1.31 and a beta of 0.37. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds have recently modified their holdings of the stock. 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares in the last quarter. Bridgewater Advisors Inc. grew its holdings in Eli Lilly and Company by 0.3% during the third quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after purchasing an additional 11 shares during the last quarter. Manske Wealth Management lifted its stake in shares of Eli Lilly and Company by 2.5% in the third quarter. Manske Wealth Management now owns 448 shares of the company’s stock worth $342,000 after buying an additional 11 shares during the last quarter. Guardian Partners Inc. lifted its stake in shares of Eli Lilly and Company by 0.3% in the third quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock worth $3,302,000 after buying an additional 12 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL boosted its holdings in shares of Eli Lilly and Company by 1.6% during the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 741 shares of the company’s stock worth $565,000 after buying an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Stores Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: ATTAIN‑MAINTAIN Phase 3 topline: Lilly reported that oral orforglipron helped patients maintain nearly all prior weight loss after switching from injectable GLP‑1s and has submitted an FDA filing for obesity — a potential blockbuster oral option that would expand addressable market and lower switching friction for patients. Lilly PR: Orforglipron ATTAIN-MAINTAIN
• Positive Sentiment: Industry / media validation: Major outlets (CNBC, Barron’s, Yahoo) and partners (Chugai) highlighted positive Phase 3 results and FDA submission for orforglipron, reinforcing commercial credibility and raising adoption expectations. CNBC: Lilly obesity pill maintains weight loss
• Positive Sentiment: Analyst upgrades and upside forecasts: Bank of America flagged room for upside (projecting ~$3B sales by 2026 for Lilly’s oral obesity drug) and Daiwa upgraded the stock — supportive to sentiment and valuation. Benzinga: BofA sees upside
• Positive Sentiment: Pipeline depth: Lilly advanced eloralintide into Phase 3, adding a follow‑on obesity/diabetes candidate that strengthens long‑term growth optionality beyond the current GLP‑1 franchise. TipRanks: Eloralintide Phase 3
• Neutral Sentiment: Competitive dynamics: Novo Nordisk and others continue to file next‑gen obesity drugs; competition could pressure pricing and share over time, but Lilly’s oral option differentiates on route-of‑administration. MarketWatch: next-gen obesity drugs
• Neutral Sentiment: Brand/marketing activity: Lilly is increasing consumer visibility (e.g., Team USA / Olympics marketing), which helps uptake but has limited immediate financial impact. MMM‑Online: Olympics marketing
• Negative Sentiment: Price cuts in Canada: Reuters reported Lilly is cutting prices of Mounjaro and Zepbound in Canada by ~20%+, which could pressure international revenue and set precedents for price negotiations elsewhere. Reuters: Canada price cuts

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Daiwa America raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday. HSBC reiterated a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. BMO Capital Markets set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Thursday, December 4th. Finally, Guggenheim reissued a “buy” rating and set a $1,163.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,141.73.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.